Lecanemab/Leqembi availability at MGB: What you Need to Know (For Clinicians)

Don’t miss this important update for clinicians!

Lecanemab/Leqembi availability at MGB: What you Need to Know

Thursday, November 9th 7-8PM via Zoom

Presented by:
* Gad Marshall, MD – Director of Clinical Trials at the BWH Center for Alzheimer Research and Treatment (CART)
* Dorene Rentz, PsyD – Co-Director, Outreach, Recruitment & Engagement Core at MADRC, Co-Director of CART
* Christine Ritchie, MD, MSPH – Co-Director, Outreach, Recruitment & Engagement Core at MADRC
• Mike Erkkinen, MD – Director BWH Division of Cognitive & Behavioral Neurology
• John Dickson, MD, PhD – Neurologist, MGH Memory Disorders Division
* Art Canter – Research Participant at MADRC

This program will deepen your understanding of:
Lecanemab approval data, mechanism of action, side effects & monitoring.
How to discuss cost & treatment demands for patients
Identifying eligible candidates for treatment consideration
How to prepare patients and expedite referrals.

To register: bit.ly/TreatmentClinic

Questions: Lenore Jackson Pope (ljackson-pope@bwh.harvard.edu)